ACE inhibitors vs ARBs: Is one class better for heart failure

Article Type
Changed
Mon, 12/17/2018 - 13:19
Display Headline
ACE inhibitors vs ARBs: Is one class better for heart failure
Article PDF
Author and Disclosure Information

Mark E. Dunlap, MD
Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University School of Medicine, and Louis B. Stokes Cleveland VA Medical Center, Cleveland, Ohio

Ross C. Peterson, MD
University Hospitals of Cleveland and Louis Stokes VA Medical Center, Cleveland, Ohio

Address: Mark E. Dunlap, MD, Cleveland VA Medical Center, Research Service 151 W, 10701 East Boulevard, Cleveland, OH 44106; e-mail [email protected]

Dr. Dunlap has indicated that he serves as a consultant for and is on the speakers’ bureau of the Astra-Zeneca corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Issue
Cleveland Clinic Journal of Medicine - 69(5)
Publications
Topics
Page Number
433-438
Sections
Author and Disclosure Information

Mark E. Dunlap, MD
Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University School of Medicine, and Louis B. Stokes Cleveland VA Medical Center, Cleveland, Ohio

Ross C. Peterson, MD
University Hospitals of Cleveland and Louis Stokes VA Medical Center, Cleveland, Ohio

Address: Mark E. Dunlap, MD, Cleveland VA Medical Center, Research Service 151 W, 10701 East Boulevard, Cleveland, OH 44106; e-mail [email protected]

Dr. Dunlap has indicated that he serves as a consultant for and is on the speakers’ bureau of the Astra-Zeneca corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Author and Disclosure Information

Mark E. Dunlap, MD
Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University School of Medicine, and Louis B. Stokes Cleveland VA Medical Center, Cleveland, Ohio

Ross C. Peterson, MD
University Hospitals of Cleveland and Louis Stokes VA Medical Center, Cleveland, Ohio

Address: Mark E. Dunlap, MD, Cleveland VA Medical Center, Research Service 151 W, 10701 East Boulevard, Cleveland, OH 44106; e-mail [email protected]

Dr. Dunlap has indicated that he serves as a consultant for and is on the speakers’ bureau of the Astra-Zeneca corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 69(5)
Issue
Cleveland Clinic Journal of Medicine - 69(5)
Page Number
433-438
Page Number
433-438
Publications
Publications
Topics
Article Type
Display Headline
ACE inhibitors vs ARBs: Is one class better for heart failure
Display Headline
ACE inhibitors vs ARBs: Is one class better for heart failure
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media